Accessibility Menu
 
Allergy Therapeutics Plc logo

Allergy Therapeutics Plc

(OTC) AGYTF

Current Price$0.11
Market Cap$696.58M
Since IPO (2004)-94%
5 Year-69%
1 Year+112%
1 Month+0%

Allergy Therapeutics Plc Financials at a Glance

Market Cap

$696.58M

Revenue (TTM)

$119.70M

Net Income (TTM)

$80.30M

EPS (TTM)

$-0.01

P/E Ratio

-10.09

Dividend

$0.00

Beta (Volatility)

4.69 (High)

Price

$0.11

Volume

15,041

Open

$0.11

Previous Close

$0.11

Daily Range

$0.11 - $0.11

52-Week Range

$0.05 - $0.11

AGYTF News

No articles available.

AGYTF: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Allergy Therapeutics Plc

Industry

Pharmaceuticals

Employees

612

CEO

Manuel Llobet, MBA

Headquarters

Worthing, BN14 8SA, GB

AGYTF Financials

Key Financial Metrics (TTM)

Gross Margin

46%

Operating Margin

-53%

Net Income Margin

-73%

Return on Equity

-366%

Return on Capital

-73%

Return on Assets

-59%

Earnings Yield

-9.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$696.58M

Shares Outstanding

6.33B

Volume

15.04K

Short Interest

0.00%

Avg. Volume

1.06K

Financials (TTM)

Gross Profit

$34.50M

Operating Income

$28.16M

EBITDA

$40.40M

Operating Cash Flow

$39.42M

Capital Expenditure

$4.48M

Free Cash Flow

$43.90M

Cash & ST Invst.

$17.56M

Total Debt

$60.09M

Allergy Therapeutics Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$30.48M

+54.8%

Gross Profit

$10.01M

+34.1%

Gross Margin

32.83%

N/A

Market Cap

$696.58M

N/A

Market Cap/Employee

$1.14M

N/A

Employees

612

N/A

Net Income

$29.00M

+16.1%

EBITDA

$27.00M

-130.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$42.53M

-97.3%

Accounts Receivable

$10.94M

+67.2%

Inventory

$19.10M

+64.8%

Long Term Debt

$58.21M

+70.3%

Short Term Debt

$1.88M

+4.3%

Return on Assets

-59.42%

N/A

Return on Invested Capital

-72.88%

N/A

Free Cash Flow

$23.00M

+8.5%

Operating Cash Flow

$21.00M

+10.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
YIHCFYiChang HEC ChangJiang Pharmaceutical Co., Ltd.
$0.55+0.00%
GLASFGlass House Brands Inc.
$7.30-5.32%
BOIRFBoiron S.A.
$30.00+0.00%
JCRRFJCR Pharmaceuticals Co., Ltd.
$4.17+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$29.02+0.00%
INTCIntel
$43.87-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%

Questions About AGYTF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.